Pharming Group N.V.: Pharming submits a Marketing Authorisat

Application is based on randomized, controlled and long-term extension data for leniolisib as a treatment for APDS, a rare primary immunodeficiency This submission follows the grant of

Related Keywords

United States , Netherlands , United Kingdom , London , City Of , Amsterdam , Noord Holland , America , Ethan Metelenis , Heather Robertson , Dan Caley , Anurag Relan , Linkedin , Nasdaq , Exchange Commission , Pharming Groupnv Euronext Amsterdam , Prnewswire Pharming Groupnv , European Medicines Agency , Pharming Group , Committee For Medicinal Products Human Use , Lifespring Life Sciences Communication , Investor Relations Corporate Communications , Marketing Authorisation Application , Medicinal Products , Human Use , Chief Medical Officer , Activated Phosphoinositide , Euronext Amsterdam , North America , Middle East , Annual Report , Allergy Clin , Rev Allergy , Investor Relations , Corporate Communications , Spring Life Sciences Communication , Pharming , Group , Ubmits , Marketing , Authorisation , Application , European , Medicines , Agency , Eniolisib ,